iwWM 2022 – Roger G. Owen
Roger Owen discusses whether the choice of BTK-inhibitor matters, what clinical data tell us about the long-term performance of acalabrutinib and talks about the different association of ibrutinib and zanubrutinib with efficacy in patients with Waldenström‘s Macroglobulinemia and low frequency genetic alterations while finally reflecting his highlights from the 11th International Workshop on WM especially the role of minimal residual disease as an independent predictor of patient outcomes.
